m6A-centered Drug Response Information

General Information of the Drug (ID: M6APDG00310)
Name
7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one
Synonyms
CHEMBL224649; Coumarin deriv. 27; BDBM9478; ZINC13586720
    Click to Show/Hide
Status
Investigative
Structure
Formula
C13H10N2O2
InChI
1S/C13H10N2O2/c16-13-4-3-11-2-1-10(7-12(11)17-13)8-15-6-5-14-9-15/h1-7,9H,8H2
InChIKey
HXFIMHPPOABVMO-UHFFFAOYSA-N
PubChem CID
11401873
TTD Drug ID
D0OY1J
Target Gene(s) and Their Upstream m6A Regulator, Together with the Effect of Target Gene(s) in Drug Response
The target genes involved in drug-target interaction (such as drug-metabolizing enzymes, drug transporters and therapeutic targets) and drug-mediated cell death signaling (including modulating DNA damage and repair capacity, escaping from drug-induced apoptosis, autophagy, cellular metabolic reprogramming, oncogenic bypass signaling, cell microenvironment, cell stemness, etc.) could be regulated by m6A regulator(s) and affected their corresponding drug response. You can browse detailed information on drug-related target gene(s) mediated by m6A regulators.
Aromatase (CYP19A1)
Fat mass and obesity-associated protein (FTO)
In total 1 mechanisms lead to this potential drug response
 Regulator Info 
Response Summary Aromatase (CYP19A1) is a therapeutic target for 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one. The Fat mass and obesity-associated protein (FTO) has potential in affecting the response of 7-((1H-imidazol-1-yl)methyl)-2H-chromen-2-one through regulating the expression of Aromatase (CYP19A1). [1], [2]
References
Ref 1 Increased N6-methyladenosine causes infertility is associated with FTO expression. J Cell Physiol. 2018 Sep;233(9):7055-7066. doi: 10.1002/jcp.26507. Epub 2018 Mar 25.
Ref 2 Design, synthesis, and 3D QSAR of novel potent and selective aromatase inhibitors. J Med Chem. 2004 Dec 30;47(27):6792-803. doi: 10.1021/jm049535j.